Atlas Trials

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

Clinical trial NCT07334119 · RECRUITING

Trial details

NCT number
NCT07334119
Sponsor
Myeloid Therapeutics
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
HER2-Expressing Solid Tumors
Start date
2025-11-25
Primary completion
2027-01-31
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.